Potential use of split-beam echosounder angular information for bivalve banks cartography: a critical evaluation

Peer Reviewe

High spatial resolution and high contrast optical speckle imaging with FASTCAM at the ORM

In this paper, we present an original observational approach, which combines, for the first time, traditional speckle imaging with image post-processing to obtain in the optical domain diffraction-limited images with high contrast (1e-5) within 0.5 to 2 arcseconds around a bright star. The post-processing step is based on wavelet filtering an has analogy with edge enhancement and high-pass filtering. Our I-band on-sky results with the 2.5-m Nordic Telescope (NOT) and the lucky imaging instrument FASTCAM show that we are able to detect L-type brown dwarf companions around a solar-type star with a contrast DI~12 at 2" and with no use of any coronographic capability, which greatly simplifies the instrumental and hardware approach. This object has been detected from the ground in J and H bands so far only with AO-assisted 8-10 m class telescopes (Gemini, Keck), although more recently detected with small-class telescopes in the K band. Discussing the advantage and disadvantage of the optical regime for the detection of faint intrinsic fluxes close to bright stars, we develop some perspectives for other fields, including the study of dense cores in globular clusters. To the best of our knowledge this is the first time that high contrast considerations are included in optical speckle imaging approach.Comment: Proceedings of SPIE conference - Ground-based and Airborne Instrumentation for Astronomy III (Conference 7735), San Diego 201

EP-1270: Volumetric modulated arc therapy in high-risk neuroblatoma¥s treatment. Single institucional experience

n/

GEC-ESTRO ACROP recommendations in skin brachytherapy

Purpose: The aim of this publication is to compile available literature data and expert experience regarding skin brachytherapy (BT) in order to produce general recommendations on behalf of the GEC-ESTRO Group. Methods: We have done an exhaustive review of published articles to look for general recommendations. Results: Randomized controlled trials, systemic reviews and meta-analysis are lacking in literature and there is wide variety of prescription techniques successfully used across the radiotherapy centers. BT can be delivered as superficial application (also called contact BT or plesiotherapy) or as interstitial for tumours thicker than 5 mm within any surface, including very irregular. In selected cases, particularly in tumours located within curved surfaces, BT can be advantageous modality from dosimetric and planning point of view when compared to external beam radiotherapy. The general rule in skin BT is that the smaller the target volume, the highest dose per fraction and the shortest overall length of treatment can be used. Conclusion: Skin cancer incidence is rising worldwide. BT offers an effective non-invasive or minimally invasive and relative short treatment that particularly appeals to elder and frail population

Multilevel transition in empty substrate integrated waveguide

This paper is a postprint of a paper submitted to and accepted for publication in Electronics Letters and is subject to Institution of Engineering and Technology Copyright. The copy of record is available at the IET Digital Library.Empty substrate integrated waveguide (ESIW) is an improvement of the well-known substrate integrated waveguide. While maintaining the low cost, easy manufacturing, small size, and integration with other circuits in the same substrate, ESIW decreases the related losses by removing the dielectric substrate, thus rendering it more interesting for practical applications. A wide band transition has been already developed to connect ESIW to microstrip lines. Filters, couplers, and antennas have also been developed in ESIW. For multilevel configurations, where different ESIW devices are implemented in different stacked substrates, a transition is needed that connects ESIW lines in different substrate levels. A low reflection wideband transition is presented for connecting two stacked ESIW lines.This work was supported by the Ministerio de Economia y Competitividad, Spanish Goverment, under Research Projects TEC2013-47037-C05-3-R and TEC2013-47037-C05-1-R.Morro, JV.; Rodríguez Pérez, AM.; Belenguer Martínez, Á.; Esteban González, H.; Boria Esbert, VE. (2016). Multilevel transition in empty substrate integrated waveguide. Electronics Letters. 52(18):1543-1544. doi:10.1049/el.2016.2558S15431544521

On the Reliability of Cross Correlation Function Lag Determinations in Active Galactic Nuclei

Many AGN exhibit a highly variable luminosity. Some AGN also show a pronounced time delay between variations seen in their optical continuum and in their emission lines. In effect, the emission lines are light echoes of the continuum. This light travel-time delay provides a characteristic radius of the region producing the emission lines. The cross correlation function (CCF) is the standard tool used to measure the time lag between the continuum and line variations. For the few well-sampled AGN, the lag ranges from 1-100 days, depending upon which line is used and the luminosity of the AGN. In the best sampled AGN, NGC 5548, the H_beta lag shows year-to-year changes, ranging from about 8.7 days to about 22.9 days over a span of 8 years. In this paper it is demonstrated that, in the context of AGN variability studies, the lag estimate using the CCF is biased too low and subject to a large variance. Thus the year-to-year changes of the measured lag in NGC 5548 do not necessarily imply changes in the AGN structure. The bias and large variance are consequences of finite duration sampling and the dominance of long timescale trends in the light curves, not due to noise or irregular sampling. Lag estimates can be substantially improved by removing low frequency power from the light curves prior to computing the CCF.Comment: To appear in the PASP, vol 111, 1999 Nov; 37 pages; 10 figure

A Combine On-Line Acoustic Flowmeter and Fluorocarbon Coolant Mixture Analyzer for The ATLAS Silicon Tracker

An upgrade to the ATLAS silicon tracker cooling control system may require a change from C3F8 (octafluoro-propane) to a blend containing 10-30% of C2F6 (hexafluoro-ethane) to reduce the evaporation temperature and better protect the silicon from cumulative radiation damage with increasing LHC luminosity. Central to this upgrade is a new acoustic instrument for the real-time measurement of the C3F8/C2F6 mixture ratio and flow. The instrument and its Supervisory, Control and Data Acquisition (SCADA) software are described in this paper. The instrument has demonstrated a resolution of 3.10-3 for C3F8/C2F6 mixtures with ~20%C2F6, and flow resolution of 2% of full scale for mass flows up to 30gs-1. In mixtures of widely-differing molecular weight (mw), higher mixture precision is possible: a sensitivity of < 5.10-4 to leaks of C3F8 into the ATLAS pixel detector nitrogen envelope (mw difference 160) has been seen. The instrument has many potential applications, including the analysis of mixtures of hydrocarbons, vapours for semi-conductor manufacture and anaesthesia

Predictive Value of Carcinoembryonic Antigen in Symptomatic Patients without Colorectal Cancer: A Post-Hoc Analysis within the COLONPREDICT Cohort

We aimed to assess the risk of cancer in patients with abdominal symptoms after a complete colonoscopy without colorectal cancer (CRC), according to the carcinoembryonic antigen (CEA) concentration, as well as its diagnostic accuracy. For this purpose, we performed a post-hoc analysis within a cohort of 1431 patients from the COLONPREDICT study, prospectively designed to assess the fecal immunochemical test accuracy in detecting CRC. Over 36.5 +/- 8.4 months, cancer was detected in 115 (8%) patients. Patients with CEA values higher than 3 ng/mL revealed an increased risk of cancer (HR 2.0, 95% CI 1.3-3.1), CRC (HR 4.4, 95% CI 1.1-17.7) and non-gastrointestinal cancer (HR 1.7, 95% CI 1.0-2.8). A new malignancy was detected in 51 (3.6%) patients during the first year and three variables were independently associated: anemia (OR 2.8, 95% CI 1.3-5.8), rectal bleeding (OR 0.3, 95% CI 0.1-0.7) and CEA level >3 ng/mL (OR 3.4, 95% CI 1.7-7.1). However, CEA was increased only in 31.8% (95% CI, 16.4-52.7%) and 50% (95% CI, 25.4-74.6%) of patients with and without anemia, respectively, who would be diagnosed with cancer during the first year of follow-up. On the basis of this information, CEA should not be used to assist in the triage of patients presenting with lower bowel symptoms who have recently been ruled out a CRC

Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945

Casein kinase 2 (CK2) regulates a plethora of proteins with pivotal roles in solid and hematological neoplasia. Particularly, in acute myeloid leukemia (AML) CK2 has been pointed as an attractive therapeutic target and prognostic marker. Here, we explored the impact of CK2 inhibition over the phosphoproteome of two cell lines representing major AML subtypes. Quantitative phosphoproteomic analysis was conducted to evaluate changes in phosphorylation levels after incubation with the ATP-competitive CK2 inhibitor CX-4945. Functional enrichment, network analysis, and database mining were performed to identify biological processes, signaling pathways, and CK2 substrates that are responsive to CX-4945. A total of 273 and 1310 phosphopeptides were found differentially modulated in HL-60 and OCI-AML3 cells, respectively. Despite regulated phosphopeptides belong to proteins involved in multiple biological processes and signaling pathways, most of these perturbations can be explain by direct CK2 inhibition rather than off-target effects. Furthermore, CK2 substrates regulated by CX-4945 are mainly related to mRNA processing, translation, DNA repair, and cell cycle. Overall, we evidenced that CK2 inhibitor CX-4945 impinge on mediators of signaling pathways and biological processes essential for primary AML cells survival and chemosensitivity, reinforcing the rationale behind the pharmacologic blockade of protein kinase CK2 for AML targeted therapy